Chemoprevention of Keratinocyte Carcinomas

0Citations
Citations of this article
1Readers
Mendeley users who have this article in their library.
Get full text

Abstract

This chapter focuses on the use of retinoids in the chemoprevention of keratinocyte carcinomas (KC) and will aim to demystify their use in the clinical arena by offering a practical approach to optimize clinical benefits and minimize adverse effects. The last decade has ushered in a handful of agents with demonstrated efficacy in the prevention of KC including vismodegib, sirolimus, DNA repair enzymes, cyclooxygenase-2 (COX-2) inhibitors, and capecitabine which will be discussed. Topical imiquimod, 5-fluoruracil (5-FU), and photodynamic therapy have been detailed elsewhere (see Chaps. 2 and 4). Vismodegib is covered in detail in Chap. 22.

Cite

CITATION STYLE

APA

Lucero, O. M., Zwald, F. O. R., & Lambert, D. (2021). Chemoprevention of Keratinocyte Carcinomas. In Skin Cancer Management: A Practical Approach (pp. 335–351). Springer International Publishing. https://doi.org/10.1007/978-3-030-50593-6_21

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free